your AIM and inaugural ImmunoTech, for call. welcome in everyone, interest our you, Thank earnings to
regulatory We our the time evolution. important to on operational, an marks Today achievements fronts. forward our and reviewing in look today clinical many
past model for developing look today to immunology And at to forward, our a reminder, is medical forward how year serious better by showing that we going we motto needs. up intend a to solutions As and live you immunological unmet for over the ImmunoTech future. AIM
have into But are progress stage we see clinical which built XXXX We've opportunities. in we of as will program tremendous the you These you late we large lead unmet transitioning go value made that our indications. ourselves forward. over lethal utilizing an in course Ampligen. are see high also will Now of pipeline market extremely development immuno-pharma are some extremely robust needs, medical how
to our see as enhanced outreach launch website. and our is what desire by our done as of visit progress, of and well going. addition and and We to properly we've plans progress our you the communicate all In this our to come invite we're where website new our
presentation discuss communications. stockholders the our Over priority. as improving future. And Communicating XXXX, to a and earnings the calls have today to our this hereafter remains focused course of with for we well top we on quarterly with plans as starting frequently progress, intend our
the see media social website. that is we're expanded doing being our stronger work You our consistent and also imprint with on
because robust Now of significant size we many company we in pipeline, our number a for had have have unique an extremely material a and accomplishments. large we respects are of
is evidenced by here things that occurred you progress XXXX. see Our in some have the XX referenced
the we potential, When potential you through Ampligen. rintatolimod, papers regarding shows data publications and are independent top see regularly outlining the Ampligen you'll go to or researchers that institutions publishing great for
our that's So is referenced activity this foundation forward XXXX springing XXXX. here in for
extremely Our pipeline is robust.
X data positive lung very is and we addressing that in The fashion. well it's pipeline For activity breast cancer, COVID, this we've triple pipeline pancreatic made accomplishments cancer, boast the on And as cancer. the now. company is can our few of right that recurrent a in very advanced needs, of size, medical as stage clinical been place a negative clinical in evolving trials these advanced ovarian evolving unmet serious have
this can been hard see game and are to our along Ampligen papers you abstracts these have path. published and You product working move in forward can read about we it that in that the developmental
an have in well areas. also and find extremely high move multiple Now clinical safety to safety value has we profile developed into us that trials allowed Ampligen with you disease profile will that
intravenous have found We well that XXX,XXX be for humans tolerated. and profile drug to the a involves generally in use doses has been approximately
a studies, establish human cancer those of have We clinical as trials our for so. advanced with have safety of recurrent part intraperitoneal trials forward done done successfully ovarian to going and purposes safety
to of we doses study future with clinical related intranasal study I dosage a in what Again, utilizing tolerated being have prolonged for into Further, the antigen an that be levels. going clinical every generally time forward different foundation our accomplished well over it basis in safety us with for found a at two think - activity will efficacy. a allowing major trials period weeks a
spectrum Long So for a drug solid implications. safety that ME/CFS, with that with spectrum as different in number an that and us a broad this Covid, forward we've of see naturally a as allows approach action broad moved tumors antiviral mechanism oncology oncology, very of foundation, its and you'll has
the Now have top program. as what I company's I'd discuss to prioritized like
We at there's fuse, have placed the a and a Late pancreatic very oftentimes. is top reason that. of cancer list in our death our cancer very stage basically and sentence short work for with pancreatic a sometimes
survival our was agent The stage government with pancreatic care. late treated of first of that overall started is of a study cancer we've standard progression with in Ampligen program as and both cancer of in there today, survival We Dutch results to show over approved where data that single Ampligen Early XXXX Program. subjects patients. it over extends Access well-established pancreatic the XX And free as as treating late a significantly
Ampligen can AstraZeneca's X cancer. and is working now checkpoint diseases seen locally where we any, enhancements advanced tremendous are but the over instances clinical of and combination these tumors on our responses is That trial drug, study combining the commenced potential through pancreatic antigen potential based and blockade Phase study gotten ever experiment Phase in to even of that for lead alone drug with to Ampligen X other are the therapy. to launch few, pancreatic possibly to we've another a FDA Now in efficacy with the if and And we And in that, we therapy many trials goal authorization part create this in with therapies checkpoint responses heighten destroy have as a complete a seen. clinical durvalumab. have that a complete as blockade
If University talk we the look at advanced our clinical ongoing Pittsburgh I'd first We ovarian our program. started Medical that like about were two programs, cancer trials to at recurrent School. of had
to to funded pembrolizumab. second a Merck where safety. X, X Phase they're and was principally located. is we're a sensitive attack these trial, trial into peritoneal one Grant Merck injected using where of order plus first cavity a part cisplatin intraperitoneal Ampligen is Phase in the establish that the better tumors protocol the Ampligen But as is drug which Phase by or subject, is KEYTRUDA the X a in The
related American convention extremely balance was XX% Now progress at Cancer subjects were significant plus for tremendous -- there They percent the combined by clinical that complete the XX% benefit with up slightly to was in the these additional and April results. because responses Association initial of initial showed of late Research was seeing of dramatic achieving an which to in pembrolizumab a Ampligen the XX abstract, a in going data published an breaking abstract, responses partial excess excess total XX stabilization. disease in
negative Roswell look the create blockade Cancer with has checkpoint Comprehensive effect combining Ampligen cancer, triple is we drugs. to pembrolizumab when abstract that Ampligen when potential especially through us was states published shows tremendous strong these at synergistic that for Center in again breast with this a combined What
cancer, to express hoping express same which the cancer, pancreatic we're that with these saw PD-LX, tends of with see with to to KEYTRUDA in working the as durvalumab So in that's tend PD-X. therapy type that pancreatic synergy why tumors we combination
Ampligen a syndrome. Now, believe disease And chronic fatigue conditions. us Covid work like of called therapy work to amount led in tremendous called as have the we've a fatigue done done would have in syndrome potential in what's or also some post-COVID Long fatigue with we that that chronic chronic
is there almost in being a lot many identity. there and reason similarities are the of respects is complete And
symptoms fog, form you cognitive and like joint see in profound including well is Now in ME/CFS malaise, serious you exact sleep which is And see traditional of as fatigue. same fatigue, that dysfunction exertional pain. post post-COVID, as fatigue disorders brain this a chronic the conditions
Phase began that that we has we been And that in compassionate FDA. by study. that for authorized pilot access ME/CFS. utilizing that or program study are for the the a But authorized commencing and program care X the the FDA with Now early process a associated of was
arrived in clinics people modified begin U.S. treating where allow the ME/CFS the Ampligen. with two the severe post-COVID. approved We that was the protocol subjects treating symptoms us to symptoms for to are And that same and those have with
a of have to we So very and Phase the to work were X With we positive effect. that the in that XXXX that moving might data, utilizing ahead did able intend we suggested therapeutic strongly in that speed QX program. full get Ampligen authorized be initial
I'd efficacy Now you that importance might X it have we and like a to is little ME/CFS. understand bit just very Ampligen's be to it's data in about in why syndrome. show like a fatigue Phase This of post-COVID important chronic
of one this have first a which group. entire Ampligen improvement compared is response the Ampligen see you study. XX% was graphs population the controlled as showing very at two about you'll here Phase for significant. is X XX% And Now with The rate, to placebo And
not -- more many in was that move But whom took study, this activity. for forward so it disease because XX had of the many to recognized we had we of were was years whom before than disease could with the this clinical even years that point the subjects that subjects some many,
to kind responsive XX% and placebo XX% is a Ampligen Ampligen the responders is the a to of from When took improvement group where and X-years see onset to significant which a placebo might which symptoms at the the we control. a XX% less Ampligen were see or subset wanted more compared be between improvement we we midpoint of what
syndrome stages a see us if of are to the like that earlier improvement of these tells onset greater So response. in from chronic treated fatigue in the we or greater disease early that position a conditions, the
fatigue post-COVID the with these being conditions, course, syndrome. in we catch of the chronic early benefit have able to people Of like
why we're store. moving what that's data to So and possible trial see as in started get the has this as fast clinical
to like our little bit and finances a I'd our Now, about plans. talk
established include the in fully AIM have we upon clinical can going to by plans But major based that we've also You see Phase two XXXX. are ImmunoTech. trials, funded which plans X foundation those be great
cash look very place. we have we and at to take key milestones. many us comfortable So in with we're these utilizing the have clinical cash we in that of to are we approaching that this aggressively believe where judiciously cash have through sufficient we And
be to to clearly a continues poised company big we had transformational so our XXXX, for we'll for value. we're successes also year is make The positive in where the in stockholder XXXX opportunities term if and ImmunoTech. going long Now be changes and AIM create in increases data
we're have number university research in in achieve For QX going These recently on to now we numerous that of QX, big see world. also that relate companies milestones we being some with doing expect recently of XXXX and we data the during be different work and milestones instances you'll pharma are top similarly advanced QX. that The because and the a in to compiled. expect as centers the some collaboration work is to will the in completed publications and is occur that
hit do to our important and other during milestones to may possible, us to We're forward achieving and publications advance XXXX. very milestones the in XXXX. forward of of to these look number a and of course every that one available best become these if going look each So
our an fact important. work the that for doing, we we're extremely The is a work we especially our here that appreciate And stockholders part and the your of doing appreciate you we're company are that interest, life for that doing we're just creates these it you, that immune-oncology better but future, in for doing for areas need for immunotherapy, itself. especially disease but a people hope in not we're also really
opportunities. clinical So to and establish of our data continue growing expand milestones. We and clinical regulatory hope to intend our achieved achieving to and continue we've our body
We with and people elevate AIM to programs doing we're launching doing the we're to have as a company today one that work such are going so it. that an as story understand we're why to opportunity the more what
actual are the you hear in making are investors. so program speak research, to doctors the and the intend to the changes we the to mouth clinical from who We doing from leaders, institutional people we're stock that key bring what to so our our think more to horse's work can who doing attractive necessary are we opinion fundamental make doing are
I done, going for a are of what hard things The these that expectation of in we're of all in evidence have future that allows and progress you work to think, success. we the we've see So very progress. to reasonable
that why get important the it's day. We All every to team understand having for up AIM. said, been behind you
Our exist under a make a wide by therapy passion is in in lives needs, in that unmet meaningful cure providing a we of have people who hope an the opportunity difference the of to range fear oncology. of medical to people's especially
progress where basically Some making death extremely we're are of these lethal, cancers a sentence. that cancers are
we to ultimately is and business. So tremendous That's again equates is it because us, these that things believe accomplish there's good good to important. this in where can very good And our science very, business need medicine where passion. also areas we a good
McAleer, this Chris time. we you. I'm our have. up you Officer, any ready have And questions Again, to program us, open we between questions me at two and the to Science with thank may thank for you your Dr. answers of I again, answer hope can the very much interest.
